Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by
modulating glutamatergic transmission through selective noncompetitive blockade of AMPA …

Perampanel (PER) is a novel antiepileptic drug recently introduced for the adjunctive
treatment in epilepsy patients aged 12 years or older with partial-onset seizures with or …

Perampanel is the latest approved antiepileptic drug in focal and generalized epilepsies and
has a distinct and selective mode of action on AMPA-receptors. Several thousand patients …

Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene‐Magistris N, Squillacote D, Kumar
D. Tolerability and safety of perampanel: two randomized dose‐escalation studies. Acta …

Perampanel (PER) has been tested in three randomized placebo‐controlled prospective
phase III trials as an adjunctive antiepileptic drug (AED) in adult and adolescent patients age …

This article reviews the profile of perampanel, a novel noncompetitive α‐amino‐3‐hydroxyl‐
5‐methyl‐4‐isoxazole‐propionate (AMPA) receptor antagonist, and its role as a potential …

Purpose Perampanel is a first-in-class antiepileptic medication approved for the treatment of
partial (focal) seizures, and as adjunctive treatment for primarily generalized tonic–clonic …

Perampanel (PER) is a novel noncompetitive AMPA-receptor antagonist approved in over
40 countries for treatment of partial seizures. The safety and tolerability of PER have been …

Evaluation of: French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel
in patients with refractory partial-onset seizures: Results of randomized global Phase III …

Introduction: Epilepsies are among the most common diseases of the CNS. As available
antiepileptic drugs do not successfully control seizures in one-third of these patients, the …